Lymphoma, B-Cell: all 1,415 studies
Page 10 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaTerminatedNCT04002622Phase 2
- A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT03999697Phase 1
- Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell LymphomaActive, not recruitingNCT03995147Phase 2
- Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell LymphomaCompletedNCT03994913Phase 1/2
- Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
- Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell LymphomaCompletedNCT03939182Phase 1
- Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.Status unknownNCT03929107Phase 2
- Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
- Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory LymphomaStatus unknownNCT03921879Phase 1
- Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell LymphomasWithdrawnNCT03920631Phase 1
- Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat LymphomaCompletedNCT03900377Phase 1/2
- ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and LymphomaStatus unknownNCT03895944Early Phase 1
- Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell LymphomaTerminatedNCT03892525Phase 1
- Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaCompletedNCT03892044Phase 1
- A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesActive, not recruitingNCT03888105Phase 2
- Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.TerminatedNCT03886649Phase 1
- CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell LymphomaStatus unknownNCT03881761Phase 1
- Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell LymphomaWithdrawnNCT03880279Phase 1/2
- Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma PatientsTerminatedNCT03876028Phase 1
- A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT03873025Phase 1/2
- Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)CompletedNCT03870945Phase 1
- Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaTerminatedNCT03864419Phase 1
- CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT03854994Phase 1
- Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma PatientsWithdrawnNCT03850028Not applicable
- DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
- Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell LymphomaStatus unknownNCT03824964Early Phase 1
- Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell LymphomaStatus unknownNCT03824951Early Phase 1
- Study of TG-1801 in Subjects With B-Cell LymphomaCompletedNCT03804996Phase 1
- The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
- A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesTerminatedNCT03797261Phase 1
- Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell LymphomaStatus unknownNCT03797170
- Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCLStatus unknownNCT03795571Phase 1
- Study of Cosibelimab in Subjects With Relapsed or Refractory LymphomaTerminatedNCT03778073Phase 1
- Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03777085Phase 3
- Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaCompletedNCT03770416Phase 2
- A Phase I Study of YY-20394 in Patients With B Cell Hematologic MalignanciesStatus unknownNCT03757000Phase 1
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLCompletedNCT03740529Phase 1/2
- Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell TherapyStatus unknownNCT03720496Phase 1
- Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.Status unknownNCT03720457Phase 1
- Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaStatus unknownNCT03719989Phase 2
- Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell LymphomaWithdrawnNCT03719560Phase 2
- Lenalidomide Based Immunotherapy in the Treatment of DLBCLStatus unknownNCT03715296
- Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaSuspendedNCT03704714Phase 1/2
- Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell LymphomaStatus unknownNCT03692767Early Phase 1
- Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell LymphomaStatus unknownNCT03690310Early Phase 1
- A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell LymphomaCompletedNCT03688152Phase 1
- CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCTStatus unknownNCT03685786Phase 1
- Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell LymphomaCompletedNCT03682796Phase 1
- Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?Status unknownNCT03681938
- A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT03671018Phase 1/2
- A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03670901Phase 3
- A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma PatientsTerminatedNCT03670888Phase 1
- MB-CART20.1 LymphomaCompletedNCT03664635Phase 1/2
- Refractory Diffuse Large B-cell LymphomaCompletedNCT03664336
- Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell NeoplasmstumorStatus unknownNCT03664297Phase 1
- AEDV Registry of Primary Cutaneous LymphomaStatus unknownNCT03646422
- Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)Status unknownNCT03639181Phase 2
- Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma PatientsCompletedNCT03630159Phase 1
- DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLActive, not recruitingNCT03620578Phase 2
- A Trial of Radiotherapy and Durvalumab in DLBCL and FLCompletedNCT03610061Phase 1
- Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or LymphomaWithdrawnNCT03605589Phase 1
- Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)TerminatedNCT03598608Phase 1/2
- XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy SubjectsStatus unknownNCT03598179Phase 2
- A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell LymphomaTerminatedNCT03593109Phase 1
- Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesStatus unknownNCT03588598Phase 1
- CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell LymphomaWithdrawnNCT03579927Phase 1/2
- CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
- A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownNCT03579082Phase 4
- Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell LymphomaCompletedNCT03576443Phase 2
- A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT03571308Phase 1/2
- Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance TherapyStatus unknownNCT03569696Phase 2
- CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell TransplantationStatus unknownNCT03564977Not applicable
- Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaTerminatedNCT03558750Phase 1
- PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCLCompletedNCT03543813Phase 1/2
- Treatment of Elderly Patients With Diffuse Large B-cell LymphomaStatus unknownNCT03513601Phase 4
- Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19Status unknownNCT03497533Phase 1/2
- RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell LymphomaCompletedNCT03485118Phase 2
- A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL SubjectsCompletedNCT03483688Phase 1
- R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)Status unknownNCT03479918Phase 3
- Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT03478514Phase 2
- A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLCompletedNCT03467373Phase 1
- Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell LymphomaCompletedNCT03458546Phase 1
- Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesCompletedNCT03424603Phase 1
- INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedNCT03424122Phase 1
- Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose TherapyTerminatedNCT03422523Phase 2
- Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?Status unknownNCT03417414
- Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell LymphomaCompletedNCT03415399Phase 1
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT03410901Phase 1
- Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell LymphomaStatus unknownNCT03399747Phase 2
- Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell LymphomaCompletedNCT03399513Phase 2
- CART-19 Cells for R/R B-cell LymphomaStatus unknownNCT03391726Phase 2/3
- Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's LymphomaTerminatedNCT03379493Phase 1
- Apatinib for Relapsed and Refractory Diffuse Large B Cell LymphomaCompletedNCT03376958Phase 4
- Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03373019Phase 2
- Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell LymphomaCompletedNCT03372837Phase 3
- Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCLStatus unknownNCT03367143Phase 2
- R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL PatientsCompletedNCT03364439Phase 2
- Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT03355859Phase 1
- Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
- Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLsStatus unknownNCT03346642Phase 1/2